massimo breccia
massimo breccia
Verified email at
Cited by
Cited by
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ...
N Engl J Med 369, 111-121, 2013
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Experts in Chronic Myeloid Leukemia
Blood, The Journal of the American Society of Hematology 121 (22), 4439-4442, 2013
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ...
Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
F Lo-Coco, G Cimino, M Breccia, NI Noguera, D Diverio, E Finolezzi, ...
Blood 104 (7), 1995-1999, 2004
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial …
F Lo-Coco, G Avvisati, M Vignetti, M Breccia, E Gallo, A Rambaldi, ...
Blood 116 (17), 3171-3179, 2010
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, ...
Leukemia 30 (8), 1648-1671, 2016
Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian …
NI Noguera, M Breccia, M Divona, D Diverio, V Costa, S De Santis, ...
Leukemia 16 (11), 2185-2189, 2002
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
F Efficace, M Baccarani, M Breccia, G Alimena, G Rosti, F Cottone, ...
Blood, The Journal of the American Society of Hematology 118 (17), 4554-4560, 2011
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the …
U Platzbecker, G Avvisati, L Cicconi, C Thiede, F Paoloni, M Vignetti, ...
American Society of Clinical Oncology 35 (6), 605-612, 2017
Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution
M Breccia, F Mandelli, MC Petti, M D’Andrea, E Pescarmona, SA Pileri, ...
Leukemia research 28 (11), 1165-1169, 2004
Gruppo Italiano Malattie Ematologiche dell’Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute …
F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ...
N Engl J Med 369 (2), 111-121, 2013
Therapy-related myelodysplastic syndrome–acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
R Latagliata, MC Petti, S Fenu, M Mancini, MAA Spiriti, M Breccia, ...
Blood, The Journal of the American Society of Hematology 99 (3), 822-824, 2002
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic …
MT Voso, S Fenu, R Latagliata, F Buccisano, A Piciocchi, MA Aloe-Spiriti, ...
J Clin Oncol 31 (21), 2671-7, 2013
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
I Iacobucci, G Saglio, G Rosti, N Testoni, F Pane, M Amabile, A Poerio, ...
Clinical Cancer Research 12 (10), 3037-3042, 2006
Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment
M Breccia, M Muscaritoli, Z Aversa, F Mandelli, G Alimena
Journal of Clinical Oncology 22 (22), 4653-4655, 2004
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
G Gugliotta, F Castagnetti, F Palandri, M Breccia, T Intermesoli, A Capucci, ...
Blood, The Journal of the American Society of Hematology 117 (21), 5591-5599, 2011
Melphalan treatment in patients with myelofibrosis with myeloid metaplasia
MC Petti, R Latagliata, T Spadea, A Spadea, E Montefusco, ...
British journal of haematology 116 (3), 576-581, 2002
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
F Efficace, M Baccarani, M Breccia, F Cottone, G Alimena, GL Deliliers, ...
Leukemia 27 (7), 1511-1519, 2013
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features
A Guarini, G Gaidano, FR Mauro, D Capello, F Mancini, MS De Propris, ...
Blood 102 (3), 1035-1041, 2003
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
F Palandri, F Castagnetti, N Testoni, S Luatti, G Marzocchi, S Bassi, ...
Haematologica 93 (12), 1792-1796, 2008
The system can't perform the operation now. Try again later.
Articles 1–20